Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $16M in Series A funding.
The round wads led by BVF Partners and Boulder Ventures.
Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. The company will initially discover and develop novel orally delivered, small molecule-based therapies targeting incretins and other class B GPCRs.
Ambrosia Biosciences intends to use the funds to scale up its drug discovery programs and laboratory operations in Boulder, CO.
FinSMEs
21/08/2024